{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T19:03:39Z","timestamp":1773083019283,"version":"3.50.1"},"reference-count":18,"publisher":"Japan Endocrine Society","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Endocr J"],"published-print":{"date-parts":[[2020]]},"DOI":"10.1507\/endocrj.ej20-0349","type":"journal-article","created":{"date-parts":[[2020,7,21]],"date-time":"2020-07-21T22:08:28Z","timestamp":1595369308000},"page":"1187-1192","source":"Crossref","is-referenced-by-count":5,"title":["Heterophile antibody interference associated with natural killer cell therapy"],"prefix":"10.1507","volume":"67","author":[{"given":"Daham","family":"Kim","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Institute of Endocrine Research, Yonsei University College of Medicine, Seoul 03722, Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Namki","family":"Hong","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Institute of Endocrine Research, Yonsei University College of Medicine, Seoul 03722, Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yonggeun","family":"Cho","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, Yonsei University College of Medicine, Seoul 03722, Korea"},{"name":"Department of Laboratory Medicine, Hallym University Sacred Heart Hospital, Anyang 14068, Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sang-Guk","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, Yonsei University College of Medicine, Seoul 03722, Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yumie","family":"Rhee","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Institute of Endocrine Research, Yonsei University College of Medicine, Seoul 03722, Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"386","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1 Hu W, Wang G, Huang D, Sui M, Xu Y (2019) Cancer immunotherapy based on natural killer cells: current progress and new opportunities. Front Immunol 10: 1205.","DOI":"10.3389\/fimmu.2019.01205"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2 Taefehshokr N, Baradaran B, Baghbanzadeh A, Taefehshokr S (2020) Promising approaches in cancer immunotherapy. Immunobiology 225: 151875.","DOI":"10.1016\/j.imbio.2019.11.010"},{"key":"3","doi-asserted-by":"publisher","unstructured":"3 Vivier E, Raulet DH, Moretta A, Caligiuri MA, Zitvogel L, et al. (2011) Innate or adaptive immunity? The example of natural killer cells. Science 331: 44\u201349.","DOI":"10.1126\/science.1198687"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4 Oh S, Lee JH, Kwack K, Choi SW (2019) Natural killer cell therapy: a new treatment paradigm for solid tumors. Cancers (Basel) 11: 1534.","DOI":"10.3390\/cancers11101534"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5 Liem NT, Van Phong N, Kien NT, Anh BV, Huyen TL, et al. (2019) Phase I clinical trial using autologous <i>ex vivo<\/i> expanded NK cells and cytotoxic T lymphocytes for cancer treatment in Vietnam. Int J Mol Sci 20: 3166.","DOI":"10.3390\/ijms20133166"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6 Suen WC, Lee WY, Leung KT, Pan XH, Li G (2018) Natural killer cell-based cancer immunotherapy: a review on 10 years completed clinical trials. Cancer Invest 36: 431\u2013457.","DOI":"10.1080\/07357907.2018.1515315"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7 Preissner CM, O\u2019Kane DJ, Singh RJ, Morris JC, Grebe SK (2003) Phantoms in the assay tube: heterophile antibody interferences in serum thyroglobulin assays. J Clin Endocrinol Metab 88: 3069\u20133074.","DOI":"10.1210\/jc.2003-030122"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8 Bolstad N, Warren DJ, Nustad K (2013) Heterophilic antibody interference in immunometric assays. Best Pract Res Clin Endocrinol Metab 27: 647\u2013661.","DOI":"10.1016\/j.beem.2013.05.011"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9 Spencer CA, Lopresti JS (2008) Measuring thyroglobulin and thyroglobulin autoantibody in patients with differentiated thyroid cancer. Nat Clin Pract Endocrinol Metab 4: 223\u2013233.","DOI":"10.1038\/ncpendmet0757"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10 Rodgers SE, Lew JI (2011) The parathyroid hormone assay. Endocr Pract 17 Suppl 1: 2\u20136.","DOI":"10.4158\/EP10297.RA"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11 Cavalier E, Carlisi A, Chapelle JP, Orfanos P, Uzan M, et al. (2009) Human anti-mouse antibodies interferences in Elecsys PTH assay after OKT3 treatment. Transplantation 87: 451\u2013452.","DOI":"10.1097\/TP.0b013e31819575a1"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12 Terunuma H, Deng X, Nishino N, Watanabe K (2013) NK cell-based autologous immune enhancement therapy (AIET) for cancer. J Stem Cells Regen Med 9: 9\u201313.","DOI":"10.46582\/jsrm.0901003"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13 Ding L, Shankara-Narayana N, Wood C, Ward P, Sidhu S, et al. (2013) Markedly elevated serum thyroglobulin associated with heterophile antibodies: a cautionary tale. Thyroid 23: 771\u2013772.","DOI":"10.1089\/thy.2012.0477"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14 Serei VD, Marshall I, Carayannopoulos MO (2019) Heterophile antibody interference affecting multiple Roche immunoassays: a case study. Clin Chim Acta 497: 125\u2013129.","DOI":"10.1016\/j.cca.2019.07.010"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15 Laudes M, Frohnert J, Ivanova K, Wandinger KP (2019) PTH immunoassay interference due to human anti-mouse antibodies in a subject with obesity with normal parathyroid function. J Clin Endocrinol Metab 104: 5840\u20135842.","DOI":"10.1210\/jc.2019-01321"},{"key":"16","unstructured":"16 Hoffman T (1990) Anticipating, recognizing, and preventing hazards associated with <i>in vivo<\/i> use of monoclonal antibodies: special considerations related to human anti-mouse antibodies. Cancer Res 50: 1049s\u20131050s."},{"key":"17","doi-asserted-by":"crossref","unstructured":"17 Akbari B, Farajnia S, Ahdi Khosroshahi S, Safari F, Yousefi M, et al. (2017) Immunotoxins in cancer therapy: review and update. Int Rev Immunol 36: 207\u2013219.","DOI":"10.1080\/08830185.2017.1284211"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18 Hong G, Chen X, Sun X, Zhou M, Liu B, et al. (2019) Effect of autologous NK cell immunotherapy on advanced lung adenocarcinoma with EGFR mutations. Precis Clin Med 2: 235\u2013245.","DOI":"10.1093\/pcmedi\/pbz023"}],"container-title":["Endocrine Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/endocrj\/67\/12\/67_EJ20-0349\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,2]],"date-time":"2021-01-02T03:43:34Z","timestamp":1609559014000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/endocrj\/67\/12\/67_EJ20-0349\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020]]},"references-count":18,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1507\/endocrj.ej20-0349","relation":{},"ISSN":["0918-8959","1348-4540"],"issn-type":[{"value":"0918-8959","type":"print"},{"value":"1348-4540","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020]]}}}